Ignite Creation Date:
2024-05-05 @ 10:29 PM
Last Modification Date:
2024-10-26 @ 10:19 AM
Study NCT ID:
NCT01114464
Status:
TERMINATED
Last Update Posted:
2016-08-08
First Post:
2010-04-28
Brief Title:
Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer
Sponsor:
Nantes University Hospital
Organization:
Nantes University Hospital
Study Overview
Official Title:
Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer
Status:
TERMINATED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
end of normal study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Resova
Brief Summary:
The aim of this protocol is to study the deleterious impact of adjuvant chemotherapy or neoadjuvant chemotherapy on ovarian reserve in young women suffering from breast cancer A new relevant ovarian reserve marker serum Anti-Mullerian Hormone will be used in order to evaluate precisely the impact of chemotherapy on ovaries during chemotherapy administrations and after during follow-up 24 months This strategy offers 2 main advantages no modification of the traditional care of patients treatment organisation follow up and use of a non invasive marker serum The final objective is to give precise information to patients on their future fertility after remission
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None